

**Amendments to the Specification:**

**Please replace paragraph [00072] on page 23 with the following amended paragraph:**

[00072] Immunoreactive pp65 proteins are presented through the MHC class I pathway since pp65-tetramer<sup>+</sup> CD8<sup>+</sup> T-cell clones from a HLA A2<sup>+</sup> CMV sero-positive donor are able to lyse HLA A2<sup>+</sup> cells genetically modified with a plasmid expressing Hypp65. See Figure 3. Controls include hygromycin-resistant U293T cells electroporated with the pMG plasmid incubated with and without the CMV pp65 peptide NLVPMVATV (SEQ ID NO:2 8 ). T2 cells are HLA A2<sup>+</sup> T-B lymphoblast hybrids incubated with and without the CMV pp65 peptide.

**Please replace paragraph [000122] on page 44 with the following amended paragraph:**

[000122] For ~~Figure 16A, Figures 16A and 16B,~~ HLA A2<sup>+</sup> MP1- and CD19- bi-specific T cells were incubated at 37°C with  $\gamma$ -irradiated CD19<sup>-</sup> K562 cells, or autologous Hy<sup>+</sup> AP-T cells, HyMP1<sup>+</sup> AP-T cells, CD19<sup>+</sup> Daudi cells, or 1:1 mixture of MP1<sup>+</sup> AP-T cells and CD19<sup>+</sup> Daudi cells. After 48 hours of culture, assays detected a 5 to 8-fold increase in TNF $\alpha$  and IFN- $\gamma$  when co-cultured with CD19<sup>+</sup> Daudi, and a 7 to 12-fold increase when co-cultured with MP1<sup>+</sup> AP-T cells, compared to control cultures (effector cells cultured in the absence of stimulator cells). The low background level of cytokine released from both target cells in the absence of MP1-tetramer<sup>+</sup>Fc<sup>+</sup> T cells and effector cells cultured with CD19<sup>-</sup> K562 cells or Hy<sup>+</sup> AP-T cells ensured that the cytokine produced was specific for the introduced and endogenous immunoreceptor contacting their respective antigen. These data confirm that the MP1-tetramer<sup>+</sup>Fc<sup>+</sup> T cells are activated in response to either CD19 or MP1 antigens.